Pulmonary atresia epidemiology and demographics

Xyz Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pulmonary atresia epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pulmonary atresia epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary atresia epidemiology and demographics
CDC on Pulmonary atresia epidemiology and demographics
Pulmonary atresia epidemiology and demographics in the news
Blogs on Pulmonary atresia epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Pulmonary atresia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  :Muhammad Waqas, M.D.[2]

Epidemiology and Demographics

Incidence

• The incidence of Pulmonary atresia subtype Intact VSD is approximately 4-8 per 100,000 individuals worldwide.
• Overall, the estimated frequency of Pulmonary atresia among all congenital heart disease is 1-3 %
• While there is no difference in the incidence of Pulmonary atresia in males or females, it is found that pulmonary atresia with VSD ( PA-VSD ) is slightly more prevalent in males compared to females.

Prevalence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
• The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

• In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
• The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

• Patients of all age groups may develop [disease name].
• The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
• [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
• [Chronic disease name] is usually first diagnosed among [age group].
• [Acute disease name] commonly affects [age group].

Race

• There is no racial predilection to [disease name].
• [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

• It is found that pulmonary atresia with VSD ( PA-VSD ) is slightly more prevalent in males compared to females.

Region

• The majority of [disease name] cases are reported in [geographical region].

• [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].